Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Receivables (2017 - 2019)

Arcus Biosciences (RCUS) has 3 years of Receivables data on record, last reported at $62000.0 in Q2 2019.

  • For Q2 2019, Receivables fell 84.22% year-over-year to $62000.0; the TTM value through Jun 2019 reached $62000.0, down 84.22%, while the annual FY2018 figure was $183000.0, 266.0% up from the prior year.
  • Receivables reached $62000.0 in Q2 2019 per RCUS's latest filing, down from $183000.0 in the prior quarter.
  • Across five years, Receivables topped out at $5.1 million in Q3 2018 and bottomed at $50000.0 in Q4 2017.
  • Average Receivables over 3 years is $982666.7, with a median of $145500.0 recorded in 2018.
  • Peak YoY movement for Receivables: surged 266.0% in 2018, then plummeted 84.22% in 2019.
  • A 3-year view of Receivables shows it stood at $50000.0 in 2017, then soared by 266.0% to $183000.0 in 2018, then crashed by 66.12% to $62000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Receivables were $62000.0 in Q2 2019, $183000.0 in Q4 2018, and $5.1 million in Q3 2018.